Business Description
Acarix AB
ISIN : SE0009268717
Total Employee Number:
8Compare
Compare
Traded in other countries / regions
ACARIX.SwedenACIXF.USA7AC.Germany IPO Date
2022-06-14Description
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.85 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 3.47 | |||||
Beneish M-Score | -3.3 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -31.7 | |||||
3-Year EBITDA Growth Rate | 47.8 | |||||
3-Year EPS without NRI Growth Rate | 49.5 | |||||
3-Year FCF Growth Rate | 50.8 | |||||
3-Year Book Growth Rate | -42.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 192.67 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 96.62 | |||||
9-Day RSI | 75.83 | |||||
14-Day RSI | 60.17 | |||||
3-1 Month Momentum % | -7.51 | |||||
6-1 Month Momentum % | -33.14 | |||||
12-1 Month Momentum % | 3.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.72 | |||||
Quick Ratio | 4.77 | |||||
Cash Ratio | 3.94 | |||||
Days Inventory | 1859.9 | |||||
Days Sales Outstanding | 108.03 | |||||
Days Payable | 510.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -56.4 | |||||
Shareholder Yield % | -1.99 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 84.42 | |||||
Operating Margin % | -526.78 | |||||
Net Margin % | -530.88 | |||||
EBITDA Margin % | -469.82 | |||||
FCF Margin % | -448.6 | |||||
OCF Margin % | -440.58 | |||||
ROE % | -96.64 | |||||
ROA % | -84.99 | |||||
ROIC % | -218.6 | |||||
3-Year ROIIC % | -94.53 | |||||
ROC (Joel Greenblatt) % | -1146.65 | |||||
ROCE % | -92.84 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 3.47 | |||||
PS Ratio | 35.57 | |||||
PB Ratio | 8.03 | |||||
EV-to-EBIT | -6.45 | |||||
EV-to-EBITDA | -7 | |||||
EV-to-Revenue | 32.91 | |||||
EV-to-FCF | -7.31 | |||||
Price-to-GF-Value | 1.45 | |||||
Earnings Yield (Greenblatt) % | -15.5 | |||||
FCF Yield % | -12.26 |
Acarix AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Acarix AB Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 | In 133 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 133 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-13 | In 49 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 49 days | ||
| First quarter earnings results for 2026 | 2026-05-18 08:00 | 0.02 (-33.90%) | ||
| First quarter earnings conference call for 2026 | 2026-05-18 | 0.02 (-33.90%) | ||
| General meeting for 2025 | 2026-05-13 | 0.03 (+0.00%) | ||
| Annual report for 2025 | 2026-04-15 | 0.04 (+9.44%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-12 | 0.03 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-12 | 0.03 (+0.00%) |
Show
Entries
Guru Commentaries on OTCPK:ACIXF
No articles.
Press Release
Articles on Acarix AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers